- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
COVID-19 Vaccine: AstraZeneca accepts Russian cooperation proposal
COVID-19 Vaccine: AstraZeneca accepts Russian cooperation proposal. AstraZeneca accepts “Satellite-V” R&D partner’s proposal to cooperate and will start vaccine combination trials.
On the 11th, the Russian COVID-19 vaccine “Satellite-V” social network account announced that AstraZeneca Pharmaceuticals in the United Kingdom has accepted the cooperation proposal put forward by the “Satellite-V” COVID-19 vaccine research and development party, and AstraZeneca will start the combined clinical vaccine Experiment plan.
Previously, the “Satellite-V” vaccine research and development team had proposed to AstraZeneca to combine its own vaccine with the “Satellite-V” vaccine when retesting, so as to improve the effectiveness of the AstraZeneca vaccine.
AstraZeneca announced on its website on the 11th that it will conduct a clinical trial to evaluate the safety and immunogenicity of the combination of the AZD1222 vaccine developed by AstraZeneca and the University of Oxford and the “Satellite-V” vaccine.
Dmitriev, president of the Russian Direct Investment Fund (cooperative manufacturer of vaccines), said on the same day that the “satellite-V” vaccine has shown high effectiveness and can be used in combination with other vaccines. Russia welcomes AstraZeneca’s research.
The “Satellite-V” vaccine is a human adenovirus vector vaccine, which consists of two adenovirus vectors. It was registered in Russia in August this year. The AZD1222 vaccine, like the “Satellite-V” vaccine, is also an adenovirus vector vaccine. In early September, a British volunteer experienced an adverse reaction after being vaccinated with the AZD1222 vaccine, which caused the clinical trial of the vaccine to be suspended. In mid-September, the AZD1222 vaccine resumed clinical trials.
On the same day, the “Satellite-V” social networking site account also announced that it is willing to share technology with French Sanofi and British GlaxoSmithKline to help them develop vaccines. Earlier, Sanofi and GlaxoSmithKline announced that their vaccine plans were postponed due to substandard immune responses in elderly subjects.